Candel Therapeutics Files 2024 10-K

Ticker: CADL · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1841387

Sentiment: neutral

Topics: 10-K, annual-report, biotech

TL;DR

Candel Therapeutics filed its 2024 10-K. All systems go.

AI Summary

Candel Therapeutics, Inc. filed its 2024 10-K on March 13, 2025, reporting its fiscal year ended December 31, 2024. The company, focused on biological products, is based in Needham, MA. Key financial details and operational updates for the fiscal year are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Candel Therapeutics' financial performance and business operations for the fiscal year 2024, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a company in the biological products sector, Candel Therapeutics likely faces inherent risks related to research and development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Candel Therapeutics, Inc.'s primary business activity?

Candel Therapeutics, Inc. is primarily involved in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].

When did Candel Therapeutics, Inc. file its 10-K report?

Candel Therapeutics, Inc. filed its 10-K report on March 13, 2025.

What is the fiscal year end for the period covered by this 10-K filing?

The fiscal year end for the period covered by this 10-K filing is December 31, 2024.

Where is Candel Therapeutics, Inc. located?

Candel Therapeutics, Inc. is located at 117 Kendrick Street, Suite 450, Needham, MA 02494.

What is the SEC file number for Candel Therapeutics, Inc.'s 10-K filing?

The SEC file number for Candel Therapeutics, Inc.'s 10-K filing is 001-40629.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding Candel Therapeutics, Inc. (CADL).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing